JP2018516964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018516964A5 JP2018516964A5 JP2017564126A JP2017564126A JP2018516964A5 JP 2018516964 A5 JP2018516964 A5 JP 2018516964A5 JP 2017564126 A JP2017564126 A JP 2017564126A JP 2017564126 A JP2017564126 A JP 2017564126A JP 2018516964 A5 JP2018516964 A5 JP 2018516964A5
- Authority
- JP
- Japan
- Prior art keywords
- nanodispersion
- treatment
- administered
- nanodisperse
- bleomycin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- -1 bevacizumab Chemical compound 0.000 claims description 10
- 229960000397 bevacizumab Drugs 0.000 claims description 9
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 8
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 8
- 229960004117 capecitabine Drugs 0.000 claims description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 8
- 229960005277 gemcitabine Drugs 0.000 claims description 8
- 108010006654 Bleomycin Proteins 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229960001561 bleomycin Drugs 0.000 claims description 7
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 7
- 210000002603 extrahepatic bile duct Anatomy 0.000 claims description 7
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims description 7
- 230000001394 metastastic effect Effects 0.000 claims description 7
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 7
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 229930192392 Mitomycin Natural products 0.000 claims description 6
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 6
- 229960005395 cetuximab Drugs 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 6
- 235000008191 folinic acid Nutrition 0.000 claims description 6
- 239000011672 folinic acid Substances 0.000 claims description 6
- 229960001691 leucovorin Drugs 0.000 claims description 6
- 229960004857 mitomycin Drugs 0.000 claims description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 6
- 229960001756 oxaliplatin Drugs 0.000 claims description 6
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims description 6
- 229960005079 pemetrexed Drugs 0.000 claims description 6
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 claims description 5
- 229960004562 carboplatin Drugs 0.000 claims description 5
- 229940097647 casodex Drugs 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 4
- 229960005061 crizotinib Drugs 0.000 claims description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000009101 premedication Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 4
- 239000006185 dispersion Substances 0.000 claims 3
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims 1
- 108010020346 Polyglutamic Acid Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940042992 afinitor Drugs 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 claims 1
- 229940080277 cholesteryl sulfate Drugs 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229960004836 regorafenib Drugs 0.000 claims 1
- ZOPOQLDXFHBOIH-UHFFFAOYSA-N regorafenib hydrate Chemical compound O.C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 ZOPOQLDXFHBOIH-UHFFFAOYSA-N 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 239000000052 vinegar Substances 0.000 claims 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 3
- 190000008236 carboplatin Chemical compound 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229960001796 sunitinib Drugs 0.000 description 3
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 201000007487 gallbladder carcinoma Diseases 0.000 description 2
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021117394A JP2021178839A (ja) | 2015-06-09 | 2021-07-15 | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2207/MUM/2015 | 2015-06-09 | ||
| IN2207MU2015 | 2015-06-09 | ||
| PCT/IN2016/050175 WO2016199169A1 (en) | 2015-06-09 | 2016-06-08 | Picn-01 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117394A Division JP2021178839A (ja) | 2015-06-09 | 2021-07-15 | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018516964A JP2018516964A (ja) | 2018-06-28 |
| JP2018516964A5 true JP2018516964A5 (https=) | 2020-11-19 |
Family
ID=57503258
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017564126A Pending JP2018516964A (ja) | 2015-06-09 | 2016-06-08 | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
| JP2021117394A Pending JP2021178839A (ja) | 2015-06-09 | 2021-07-15 | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021117394A Pending JP2021178839A (ja) | 2015-06-09 | 2021-07-15 | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US11304898B2 (https=) |
| EP (1) | EP3307242A4 (https=) |
| JP (2) | JP2018516964A (https=) |
| WO (1) | WO2016199169A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3307242A4 (en) * | 2015-06-09 | 2019-01-23 | Sun Pharma Advanced Research Company Limited | PICn-01 |
| CN107019706A (zh) * | 2017-03-31 | 2017-08-08 | 福州大学 | 一种顺铂‑醛基化透明质酸纳米复合物及其制备方法 |
| CN114728189A (zh) * | 2019-11-11 | 2022-07-08 | 日本先端株式会社 | 抗癌剂暴露防止方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ586343A (en) | 2007-12-24 | 2012-03-30 | Sun Pharma Advanced Res Co Ltd | Nanodispersion comprising taxane derivatives, fatty acids and sterols |
| CN102802624A (zh) | 2009-06-19 | 2012-11-28 | 太阳医药高级研发有限公司 | 药物的纳米分散体以及它的制备方法 |
| EP2394640A1 (en) * | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
| EP2747761A1 (en) | 2011-09-22 | 2014-07-02 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
| EP3307242A4 (en) * | 2015-06-09 | 2019-01-23 | Sun Pharma Advanced Research Company Limited | PICn-01 |
-
2016
- 2016-06-08 EP EP16807045.6A patent/EP3307242A4/en not_active Withdrawn
- 2016-06-08 US US15/580,732 patent/US11304898B2/en active Active
- 2016-06-08 WO PCT/IN2016/050175 patent/WO2016199169A1/en not_active Ceased
- 2016-06-08 JP JP2017564126A patent/JP2018516964A/ja active Pending
-
2021
- 2021-07-15 JP JP2021117394A patent/JP2021178839A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tummala et al. | Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer | |
| Gad et al. | Targeting cancer using polymeric nanoparticle mediated combination chemotherapy | |
| JP2019529388A5 (https=) | ||
| Saisyo et al. | pH-sensitive polymeric cisplatin-ion complex with styrene-maleic acid copolymer exhibits tumor-selective drug delivery and antitumor activity as a result of the enhanced permeability and retention effect | |
| JP6580799B2 (ja) | 標的疎水性抗腫瘍薬物ナノ製剤及びその調製方法 | |
| Raut et al. | Sorafenib tosylate novel drug delivery systems: Implications of nanotechnology in both approved and unapproved indications | |
| JP2017505800A5 (https=) | ||
| CN101730526A (zh) | 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒 | |
| JP2017503014A5 (https=) | ||
| JP2018516964A5 (https=) | ||
| Li et al. | Cisplatin-based combination therapy for enhanced cancer treatment | |
| Fu et al. | Will arsenic trioxide benefit treatment of solid tumor by nano-encapsulation? | |
| Xiao et al. | Use of anticancer platinum compounds in combination therapies and challenges in drug delivery | |
| JP2021178839A (ja) | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 | |
| JP2019038797A5 (https=) | ||
| Fahmy et al. | PEGylated chitosan nanoparticles loaded with betaine and nedaplatin hamper breast cancer: in vitro and in vivo studies | |
| Keerikkadu et al. | Dasatinib pharmacokinetics and advanced nanocarrier strategies: from systemic limitations to targeted success | |
| Voigt et al. | A new chemoembolization protocol in refractory liver metastasis of colorectal cancer–a feasibility study | |
| Müller et al. | Curative and palliative aspects of regional chemotherapy in combination with surgery | |
| WO2017084522A1 (zh) | 一种新型抗癌药物纳米制剂及其制备方法 | |
| Li et al. | Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer | |
| Le et al. | Anticancer efficacy of oral docetaxel nanoformulation for metronomic chemotherapy in metastatic lung cancer | |
| CN102018670B (zh) | 一种抗癌制剂 | |
| Fujiwara et al. | Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study | |
| Muchmore et al. | Regional chemotherapy: overview |